CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...
MedPage Today on MSN22h
FDA OKs New Option for Uncomplicated UTIs in Women, Girls
The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...
Clinical Trials Arena on MSN2d
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
MedPage Today on MSN10d
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian Cancer
Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
BioWorld12d
Charles University and MFMER divulge new DNA topoisomerase II β inhibitors to treat cardiotoxicity
Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...
Longview News-Journal28d
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate ... maximum tolerated dose and recommended Phase II dose and schedule of ADCE-T02 monotherapy ...
Monthly Prescribing Reference12y
Ciprofloxacin Iv Concentrate
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial ...